Tag Archives: David Brennan

Brennan Departure: What Now for AZ?

By Julian Upton | Published: April 26, 2012
AstraZeneca’s shares may have fallen by as much as 6.3% following news of David Brennan’s imminent departure — the biggest intraday decline since December 17, 2010, said Bloomberg — but analysts welcomed his retirement as a good thing. “This will be received positively,” said WestLB’s Mark Belsey. “It’s time for someone to reinvigorate the pipeline.” With [...]
Posted in Op-Ed | Also tagged , | Leave a comment

AZ Celebrates Crestor Patent Win

By George Koroneos | Published: June 30, 2010
The US District Court in Delaware upheld AstraZeneca’s patent for its blockbuster statin Crestor (rosuvastatin), ending a dispute that could have crippled the drugmaker’s billion-dollar cash cow. Crestor’s patent is not scheduled to expire until 2016. However, a group of generics firms had claimed that a substance patent (314) protecting one of the active ingredients in [...]
Posted in Legal | Also tagged , , , , , , | Leave a comment

AstraZeneca to Slash 8,000 More Jobs (Updated 2/3/10)

By Oriana Schwindt | Published: January 28, 2010
Last year, AstraZeneca announced the elimination of some 15,000 jobs. Last Thursday, the London-based company revealed that it plans to lay off another 8,000 by 2014—this despite global revenue growth of 4 percent for 2009. Much of the drive for this addition labor sculpting stems from AZ’s desire to streamline its R&D; the company will focus [...]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment